

Index

A

Agamonematodum migrans, 153
Albendazole, 53, 163
Allopurinol, 38
Alpacas and llamas, 135
Alveococcus cyst, 116
Alveolar echinococcosis, 117, 119
Amastigotes, 35
Aminoglycoside paromomycin, 53
Ancylostoma braziliense, 172
Ancylostoma caninum, 148, 151, 169
 aberrant, 170
 anthelmintic resistance, 173
 anthelmintic resistant, 176
 buccal capsule, 151
 female, 148
 hookworm disease, 152
 hypobiosis, 151
 hypobiotic L3, 150
 infective larvae, 152
 life cycle stages, 148, 149
 molecular diagnostics, 171
 multidrug-resistant, 176
 muscular esophagus, 151
 prevalence, 152
 skin penetrating larvae, 150
 transmission, 153
 treatment guidelines, 153
 zoonotic hookworms, 171
Anthelmintic resistance, 173, 174
 development, 173, 176
 in greyhounds, 175
 in hookworms, 175

Anthelmintics, 152
Anthelmintic therapy, 17
Anti-*Leishmania* antibodies, 36
Anti-leishmanial treatment, 39
Auto infective cycle, 205

B

Baermann technique, 210, 211
Benzimidazoles, 53, 60, 63, 152
 febantel, 62
 fenbendazole, 60
Bilharziella polonica, 279
B lymphocytes, 31

C

Canine hookworms, 169
Canine leishmaniosis (CanL)
 clinical signs/laboratory findings, 37
 diagnosis, 34, 36
 endemic regions, 34
 ferritin, 34
 insecticides, 40
 and renal failure, 34
 resistance/susceptibility, 31
 stages, 39
 treatment, 38–40
 typical picture, 33
Canis lupus familiaris
 abilities, 1
 autosomes, 2
 breeds, 2

- Canis lupus familiaris* (cont.)
 chromosomes, 2
 genome, 2
 human cultures/religions, 2
 life spans, 2
 wolves, 1
- Central nervous system (CNS), 10
- Cephalic papillae, 246
- Chagas disease, 74, 76, 79, 82
 nutritional and metabolic disorders, 74
- Chari river basin, 257
- Chloroquine, 66
- Chronic strongyloidiasis, 209
- Clinical staging system, 38
- Colonoscopy, 169
- Commercial vaccines, 40
- Community-wide insecticide spraying
 campaigns, 94
- Companion Animal Parasite Council (CAPC),
 50, 51
- Complete blood count (CBC), 37
- cox1* sequences, 216
- C-reactive protein (CRP), 34
- Creeping eruption, 153, 160
- Cryptosporidiosis, 65
- Cucumber tape worm, 142
- Culling poultry, 256
- Cutaneous larva migrans (CLM)
 follicular cases, 164
 in oral mucosal, 163
 in Philippines, 164
 prevention, 164
 treatments, 163, 164
- Cyclops*, 247, 248
- Cyst fertility, 132
- Cysticercoid larvae, 142
- Cytology, 35, 36
- D**
- Demographic surveys, 82
- Diffuse unilateral subacute neuroretinitis
 (DUSN)
 causative worm, 162
 characteristic, 161
 CLM, 162
 oral anthelmintics/laser mediated
 destruction, 161
 photocoagulation, 162
 size, 161
 SLO, 161
 subretinal space, 161
- Dipylidium caninum*, 143, 144
- Direct–indirect switch, 206
- Dirofilaria immitis*, 228
 life cycle, 228
- Dirofilaria repens*
 life cycle, 229
- Discrete typing units (DTUs), 75
- Disseminated strongyloidiasis, 208
- Dog dracunculiasis epidemiology, 253
- Dog dracunculiasis transmission, 255
- Dogs and humans
 European hard ticks and pathogens, 264
 parasites and pathways, 263
 symptoms of infections, 262
 transmission, 261
- Domestic livestock, 136
- Domestic transmission cycles, 80
- Domestic vector species, 86
- Dracunculiasis, 243, 247, 249, 256
 cases, countries, 252
 definitive hosts, 247
 eradication, 257
 human and dog, 252
 male and female worms, 247
 parasite, 248
 parasitic diseases, 247
 transmission, 248
- Dracunculoid nematodes, 244
- Dracunculosis, 246
- Dracunculus medinensis*
 life cycle, 254
 morphology, 246
 taxonomy, 244
- Dracunculus* species, 248
- Drug treatment, 95
- E**
- Echinococcus*, 117
 diagnosis, 107
 drugs lethality, 117
E. granulosus, 110, 114
E. multilocularis, 115
 genotypes, 109
 geographic distribution, 108
 molecular biological details, 107
 multilocular cysts, 114
 prophylaxis, 117
 protoscolices, 117
 species distribution, 109
 specimens, 108
 symptoms of disease, 115
- Echinococcus granulosus*, 110–114, 123
 eggs, 110
 strains, 110
- Echinococcus multilocularis*, 114–116
- Echinococcus granulosus*
 Australia eggs, 126

- dingoes, 125
 - domestic animals
 - alpacas and llamas, 135
 - annual financial, 134
 - in Australia, 136
 - Australian sheep, 134
 - cattle, 133
 - domestic dogs, 133
 - GDR, 134
 - life cycle, 124
 - prevalence, 125
 - sheep herding dogs, 124
 - tapeworms, 124
 - transmission, 124, 125
 - Echocardiography, 79
 - Egg package (EP), 144
 - Electrocardiographic surveys, 78
 - Embryonation, 6
 - Entamoeba histolytica*, 265
 - Enzyme-linked immunosorbent assay (ELISA), 16, 166
 - Eosinophilia, 209
 - Eosinophilic enteritis (EE), 165
 - A. caninum*, 165, 168, 169
 - Australian, 168
 - cause, 165
 - diagnosing, 166, 167
 - hookworms, 170
 - percutaneous infection, 167
 - rarity, 165
 - symptoms, 166, 169
 - in the United States, 169
 - Eosinophilic gastroenteritis (EG), 165
 - Eosinophilic gastrointestinal disorders (EGID), 165
 - European Scientific Counsel Companion Animal Parasites (ESCCAP), 153
 - Excretory–secretory (ES), 166
 - Exfoliative dermatitis, 32, 33
- F**
- Febantel, 62
 - Fenbendazole, 60
 - First-stage larvae (L1), 202
 - Food-borne transmission, 255
 - Free-living adult females, 202
 - Free-living adults, 202
 - Free-living males, 203
- G**
- Gallbladder/bile ducts, 274
 - GenBank, 169
 - Giardia*, 61
 - asymptomatic, 46
 - benzimidazoles, 60
 - CAPC map, 50
 - CDC data, 48
 - cysts, 47
 - diagnosis, 46
 - DNA identification, 46
 - drugs, 53
 - drug therapy, 52
 - gastrointestinal upset, 48
 - literature, 50
 - mortality, 47
 - nitroimidazoles, 54
 - oral vaccine, 52
 - outbreaks, 47
 - people and dogs, 46, 52
 - positive, 46, 50
 - prevalence, 48
 - sewage treatment, 47
 - subclinical, 45
 - treatment, 55, 63
 - ubiquitous nature, 50
- Great Dividing Range (GDR), 134
- Greyhound breeding farms, 175, 176
- Guinea worm disease (GWD), 240
 - in ancient Egypt, 240
 - crustacean intermediate host, 242
 - D. medinensis*, 240
 - D. medinensis* life cycle, 251
 - dracunculiasis, 244
 - in Egypt, 244
 - GWEP technical staff, 252
 - infection, 249
 - maintenance, 257
 - WHO, 241, 257
 - zoonotic character, 240
- Guinea worm eradication, 256
- Guinea Worm Eradication Program (GWEP), 250, 251
- Guinea worm infection, 253
 - reservoirs, 253
 - transport hosts, 256
- Guinea worm water-borne life cycle, 249
- H**
- Heartworm disease (HWD)
 - asymptomatic, 229
 - clinical presentations, 229
 - diagnosis, 230
 - prevention, 231
- Heterophyes*, 274, 278
- Heterophyes heterophyes*, 277
- Heterophyes* species, 274, 275
- Homogonic cycle

- Homogonic cycle (*cont.*)
 direct, 205
 indirect, 205
- Hookworm disease, 151
- Hookworm-related cutaneous larva margin
 (CLM/HrCLM), 154
A. braziliense, 155
 autochthonous, 155
 chronic/persistent, 156
 creeping eruption, 154
 ELISA, 157
 enigmatic case, 160
 eosinophilia, 155
 follicular, 156
 hookworm larvae, 158
 hookworm species, 157
 optic disc edema, 160
 presentations, 156
 skin scraping, 157
 soil and/or sand, 154
 in United States, 154
- Host infectiousness, 89
- Host–parasite interactions, 198
- Human dirofilariasis, 233
 pulmonary dirofilariasis, 233
 subcutaneous and ocular, 233
- Human hydatid disease, 124
- Human hydatidosis, 135
- Human parasitic nematodes, 199
- Human toxocarosis, 10
- Hydatid disease, 124, 128, 134
- Hydatid infection, 133
- Hydatid larval stages, 110
- Hyperinfection syndrome, 208, 209, 211
- Hypobiosis, 150
- Hypobiotic larvae, 150
- I**
- Immune-mediated mechanisms, 31
- Indirect hemagglutination assays, 79
- Infectiousness, 88, 89
- Infective third-stage larvae (iL3), 200, 202
- K**
- kDNA PCR assays, 36
- L**
- Lagomorphs, 132
- Laparotomy, 165, 166
- Leishmania donovani*, 28
- Leishmania infantum*, 28, 29, 35
 clinical findings, 32
 detection, 35
 epidemiology, 29
 natural transmission, 30
 pathogenesis, 30
- Leishmaniases, 28
- Leishmaniasis, 28, 32, 34
 clinical signs, 29
 enzootic, 31
 visceral, 36
- LeishVet association, 36
- LeishVet stage I, 38
- LeishVet stage II, 38
- Life cycle, 110
- Löffler's syndrome, 158, 159
- M**
- Macropodid species, 127
- Megacolon and megaesophagus, 78
- Meglumine antimoniate, 38, 39
- Meningoencephalitis, 78
- Metronidazole, 53–55, 61, 66
- Miltefosine, 38, 39
- Mixed blood meals, 87
- Molecular methods, 79, 80, 86
- Moxidectin, 176
- Myocardium, 78
- N**
- Natural Guinea worm infections, 244
- Neglected tropical diseases (NTDs), 196
- Neurotoxocarosis (NT), 10, 13
 dopamine system, 13
 murine and human, 13
 parenchymal damage and haemorrhagic
 lesions, 14
 pathogenesis, 13
- Nitazoxanide, 64
- Nitroimidazoles, 54
 metronidazole, 54
 ronidazole, 60
 secnidazole, 59
 tinidazole and ornidazole, 54
- Nonoverlapping transmission cycles, 92
- O**
- Ocular *larva migrans* (OLM) syndrome, 10, 12
 clinical indication, 12
 symptomatology, 12

Oncosphaera larva, 142
Opisthorchis, 274
Opisthorchis felineus, 274, 276
Opisthorchis tenuicollis, 275
 Ornidazole, 54
Ornithobilharzia species, 279
 Oxfendazole, 63

P

Parasitic infections, 16
 Parasitic nematodes, 173
Parastrongyloides, 204
 Peracute hookworm disease, 151
 Peridomestic transmission cycles, 80
 Peripheral blood eosinophilia (PE), 165
 Phlebotomine sand flies, 28
 Pinworm, 196
 Polymerase chain reaction (PCR) method, 29
 Praziquantel-medicated baits, 136
 Pre-molecular era, 213
 Protoscolices, 110
Pseudorhabditis stercoralis, 196
 Pulmonary dirofilariosis, 233
 Pyrantel resistance, 174
 Pyrethroids, 94

Q

Quantitative real-time PCR (qPCR), 88
 Quantitative serological test, 39
 Quinacrine, 53, 65
 Quinolines, 65
 chloroquine, 66
 quinacrine, 65

R

Rabbits (*Oryctolagus cuniculus*), 132
 Ravuconazole, 95
 Reproduction
 in free-living generations, 204
 in parasitic adults, 203
 Residual house spraying, 94
 Reverse zoonosis, 240
 Rhabditiform, 202
Rhabdonema strongyloides, 196
 Ronidazole, 60

S

Sandworm eruption, 155
 Scanning laser ophthalmoscope (SLO), 161

Schistosomatid species, 281
 Schistosomatid trematodes, 277
 diagnosis, 279
 SDS-PAGE analysis, 15
 Secnidazole, 59
 Serological cross-reactivity, 36
 Serological tests, 16
 Sex determination, 206
 Sexual and asexual reproduction, 203
 Small ribosomal SubUnit (SSU), 214
 Strongylid nematodes, 173
Strongyloides, 204, 214
 life cycle, 196
Strongyloides intestinalis, 196
Strongyloides planiceps, 217
Strongyloides stercoralis
 detection, 209
 diagnosis, 209
 diagnostic methods, 197
 epidemiology, 198
 human-derived, 213
 infections, 199, 213
 life cycle, 200
 life history, 197
 medical importance, 198
 morphology, 197, 199
 parasitic adult females, 200
 parasitic worms, 201
 prevalence, 198, 212
 risk factors, 198
 sub-clades, 215
 symptoms, 209
 transplantation centers, 212
 treatment, 211
 Strongyloidiasis
 hyperinfection syndrome, 208
 infection, 207
 parasitic adults, 196
 review articles, 197
 Subcutaneous and ocular dirofilariosis, 233
 Subcutaneous dirofilariosis (SCD), 231, 233
 Sylvatic transmission cycles, 80

T

Tapeworms
 developmental cycle, 142
 diagnosis, 144
 geographic distribution/epidemiology, 141
 infectious cysticeroid larvae, 144
 Latin name, 141
 parasitizes, 141
 symptoms, 143

- Tapeworms (*cont.*)
 terminal proglottids, 141
 Tasmanian hydatid control campaign, 135
 T-helper 1 (Th1) response, 30
 Thiabendazole, 163
 Thoracic radiography, 79
 Threadworm, 196
 Tinidazole
 and ornidazole, 54
Toxocara canis
 ascarid infection, 6
 biological characteristics, 6
 control and prevention, 18
 definitive hosts, 6
 development, 7
 diagnosis, 15
 distribution, 8
 embryonated, 6
 and immune cells/immune-related
 compounds, 14
 larvae, 6, 14
 life cycle, 9
 migration route, 10
 tracheal migration, 7
 transmission routes, 8
 treatment, 17
 VLM, 11
Toxocara eggs, 8
Toxocara-infected paratenic hosts, 10
 Toxocarosis, 6, 11, 12, 18
Toxoplasma gondii, 265
 Transmission
 eco-epidemiology
 demographic surveys, 82
 dog demography, 82
 host conditions, 82
 host-feeding patterns, 84
 prevalence, 87
 Transmission cycles
 domestic, 80
 molecular epidemiology
 molecular methods, 92
 overlapping transmission cycle, 92
 sympatric transmission cycles, 93
 peridomestic, 80
 sylvatic, 80
 Transplacental/intrauterine transmission, 7
 Trans-sialidase inhibition assay, 79
 Trematodes
 diagnosis, 276
 geographic distribution/epidemiology, 274
 prophylaxis, 276
 Triatominae, 84
 Triatomine host-feeding patterns, 84
 Triatomine species, 85
Trichobilharzia species, 277, 279
 Tropical Institute in Bukhara, 250
 Tropical lifestyle, 167
Trypanosoma caninum, 77
Trypanosoma cruzi
 canine infections, 78
 chronic infections, 79
 consumption, 76
 diversity, 74
 dogs seropositive, 79
 domestic transmission, 90, 91
 DTU and clinical presentation, 75
 eco-epidemiology, 75
 genotypes, 89
 host infection, 75
 human infection, 74
 infection, 77, 87
 infectiousness, 88, 89
 insect vector and mammalian host, 75
 peridomestic transmission, 90
 prevalence, 87
 reservoir hosts, 74, 80, 81
 residual effects, 94
 sentinels of exposure, 90
 spatial distribution, 90
 sylvatic sources, 90
 transmission, 75, 81, 93
 transmission cycles, 74
 trypanomastigotes, 75
 vaccine, 95
 vector-mediated and oral infections, 76
 zoonotic infection, 74
 Trypanosomatids, 76
- U**
 Urine protein/creatinine (UPC) ratio, 37
- V**
 Vector-borne diseases, 235
 Vector-borne infectious disease, 31
 Vector control strategy, 94
 Vector–host contact rates, 88
 Vector-mediated zoonoses, 74
 Visceral larva migrans (VLM), 11
 characteristics, 12
 classical, 11
 clinical picture, 11

syndrome, 10
Visceral leishmaniosis, 28

W

Water-borne transmission, 247, 248
Wild dogs, urban environments
 in Australia, 126
 camels, donkeys and horses, 131
 deer, 130
 feral cats, 127
 feral pigs, 132
 foxes, 126, 127
 goats, 131
 macropodid marsupials, 127, 128
 residents living, 126

 water buffalo, 130
 wombats, 128
Wombats, 128

X

Xenodiagnosis
 and hemoculture, 78
Xenointoxication, 94

Z

Zooanthroponosis, 240
Zoonosis, 240
Zoonotic infections, 248, 257